Welcome to our dedicated page for enGene Therapeutics news (Ticker: ENGN), a resource for investors and traders seeking the latest updates and insights on enGene Therapeutics stock.
enGene Holdings Inc. (NASDAQ: ENGN) is a clinical-stage, non-viral genetic medicines company whose news flow centers on its lead investigational therapy, detalimogene voraplasmid, for high-risk non-muscle invasive bladder cancer (NMIBC). Company announcements frequently highlight clinical data from the ongoing Phase 2 LEGEND trial, regulatory interactions, and manufacturing readiness for this novel bladder-instilled genetic medicine.
Investors following ENGN news can expect updates on preliminary efficacy and safety results from the LEGEND pivotal cohort and additional cohorts, including complete response rates at various time points and treatment-related adverse event profiles. enGene also reports on changes to trial endpoints following discussions with the U.S. Food and Drug Administration, as well as participation in programs such as the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program.
News releases regularly cover capital markets activities, such as underwritten public offerings of common shares and pre-funded warrants, along with liquidity updates and financial results. Governance and leadership developments, including the appointment of new board members and the hiring of a Chief Medical Officer with extensive bladder cancer experience, are also disclosed through company press releases and related Form 8-K filings.
Because detalimogene has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, regulatory and clinical milestones are key themes in enGene’s communications. For users tracking ENGN, this news page aggregates company-issued updates on clinical progress, FDA designations and programs, financing transactions, and corporate governance developments, offering a centralized view of material events that may shape the company’s development trajectory.
enGene Holdings Inc. (Nasdaq: ENGN) announced an oral presentation at the American Urology Association 2024 Annual Meeting regarding its non-viral gene therapy EG-70 for BCG-unresponsive non-muscle invasive bladder cancer. The presentation highlights the rational design of EG-70 to address challenges faced by other treatment options. Promising Phase 1 data show complete response rates of 70% and 60% at three and six months, respectively, with encouraging safety results.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.